Rare Disease Marketing Lead: Portfolio Launch

AstraZeneca plc; Sydney; Hybrid; AUD 180,000 - 280,000; Full time

Benefits offered by this job

Hybrid work arrangement

Great Place to Work recognition

Job summary

AstraZeneca, in collaboration with Alexion Rare Disease, is seeking a seasoned pharmaceutical marketer to lead strategy and execution across a growing rare disease portfolio. You will shape portfolio strategy, drive launch readiness and coordinate cross-functional teams to deliver customer-centric campaigns.

The role is based in Sydney, Australia, offering hybrid work (3 days in-office) and opportunities to advance science-driven commercial performance in a global company.

Qualifications

• Demonstrated pharmaceutical marketing experience across specialty care and lifecycle management.
• Experience launching or commercialising brands across multiple indications.
• Strong ability to prioritise investments using insight, data and forecast accuracy.

Responsibilities

• Lead strategic and operational marketing across a rare disease portfolio.
• Drive launch readiness, segmentation, positioning, messaging and forecasting.
• Own end-to-end marketing execution including campaigns, reviews, budgets and agencies.
• Design connected omnichannel experiences and leverage data and AI to improve decisions.
• Partner with Medical Affairs, Market Access, Regulatory, Sales and external agencies.
• Mentor marketing colleagues and build cross-functional capability.

Skills

Pharmaceutical marketing

Multichannel marketing

Leadership

Data analytics

AI-enabled marketing

Education

Bachelor's degree in marketing or life sciences

Tools

CRM

Job description

AstraZeneca, in collaboration with Alexion Rare Disease, is seeking a seasoned pharmaceutical marketer to lead strategy and execution across a growing rare disease portfolio. You will shape portfolio strategy, drive launch readiness and coordinate cross-functional teams to deliver customer-centric campaigns.

The role is based in Sydney, Australia, offering hybrid work (3 days in-office) and opportunities to advance science-driven commercial performance in a global company.